HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup

Dual-Target ADC Shows 15-Month Progression-Free Survival in Prostate Cancer: Tanya Dorff, MD

Dual-Target ADC Shows 15-Month Progression-Free Survival in Prostate Cancer: Tanya Dorff, MD

By AJMC · May 31, 2026 · via AJMC

This is an aggregated industry headline. Read the full story at AJMC

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineAJMC
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become…
Jul 15, 2026
The WeekFierceBiotech ↗
Attovia Therapeutics has filed for an IPO to secure funding for assets including a potential challenger to San…
Jul 15, 2026
STAT+: Medicare Advantage insurers face new bipartisan scrutiny over AI and care denials
The WeekSTAT News ↗
Blumenthal, Hawley press UnitedHealth, Humana, CVS for documents related to using AI to deny or delay care.…
Jul 15, 2026